Årsak kan være at kroppen ikke kan nyttiggjøre seg stoffskiftehormoner


Lowe, J.C. (1995) T3-Induced Recovery from Fibromyalgia by a Hypothyroid Patient Resistant to T4 and Desiccated Thyroid. Journal Myofascial Ther., 1(4):26-31. Conclusions: Studies have shown no other therapies for fibromyalgia to be significantly effective,[16] while millions of fibromyalgia patients suffer non-remitting symptoms.[17] Because of this, clinicians and researchers should not ignore the possible benefits of T3 therapy for their fibromyalgia patients.

Garrison RL1, Breeding PC. 2003 A metabolic basis for fibromyalgia and its related disorders: the possible role of resistance to thyroid hormone.   Abstract: It has long been recognized that the symptom complex of fibromyalgia can be seen with hypothyroidism. Hypothyroidism may been categorized, like diabetes, into type I (hormone deficient) and type II (hormone resistant). Most cases of fibromyalgia fall into the latter category. The syndrome is reversible with treatment, and is usually of late onset. It is likely more often acquired than due to mutated receptors. Now that there is evidence to support the hypothesis that fibromyalgia may be due to thyroid hormone resistance, four major questions appear addressable. First, can a simple biomarker be found to help diagnose it? Second, what other syndromes similar to Fibromyalgia may share a thyroid-resistant nature? Third, in non-genetic cases, how is resistance acquired? Fourth, what other methods of treatment become available through this new understanding? Preliminary evidence suggests that serum hyaluronic acid is a simple, inexpensive, sensitive, and specific test that identifies fibromyalgia. Overlapping symptom complexes suggest that chronic fatigue syndrome, Gulf war syndrome, premenstrual syndrome, post traumatic stress disorder, breast implant silicone sensitivity syndrome, bipolar affective disorder, systemic candidiasis, myofascial pain syndrome, and idiopathic environmental intolerance are similar enough to fibromyalgia to merit investigation for possible thyroid resistance. Acquired resistance may be due most often to a recently recognized chronic consumptive coagulopathy, which itself may be most often associated with chronic infections with mycoplasmids and related microbes or parasites. Other precipitants of thyroid resistance may use this or other paths as well. In addition to experimentally proven treatment with supraphysiologic doses of thyroid hormone, the thyroid-resistant disorders might be treatable with anti-hypercoagulant, anti-infective, insulin-sensitizing, and hyaluronolytic strategies.



Dr John Lowe har forsket en del på denne sammenhengen. Det er en utmerket artikkel av ham på Thyroid UK sine sider:



Studien her: Effectiveness and Safety of T3 (Triiodothyronine) Therapy for Euthyroid Fibromyalgia (2003) A Double-Blind Placebo-Controlled Response-Driven Crossover StudyConclusions. In this study, supraphysiologic dosages of T3 were safe and significantly effective in the treatment of euthyroid FMS. Though these dosages produced thyroid function test results indicative of hyperthyroidism, our patients had no clinically significant adverse target tissue effects. Results suggest that euthyroid FMS is a clinical phenotype of partial peripheral resistance to thyroid hormone. We recommend that further studies be done to answer the questions: Are euthyroid FMS patients partially resistant to thyroid hormone? And if so, what are the molecular mechanisms of the resistance? Further testing is also necessary to establish the long-term safety of T3 therapy.



En studie til av John Lowe: Thyroid Status of 38 Fibromyalgia Patients: Implications for the Etiology of Fibromyalgia (2008)
ABSTRACT Thyroid function tests were used to classify 38 fibromyalgia patients according to thyroid status. Results were consistent with euthyroidism (normal thyroid status) in 14 patients (36.8%), primary (thyroidal) hypothyroidism in 4 patients (10.5%), and central (hypothalamic or pituitary) hypothyroidism in 20 patients (52.6%). The percentages of primary and central hypothyroidism in this group of fibromyalgia patients are extremely higher than those for the general population. There was no statistical difference for the mean intensity of fibromyalgia symptoms (measured by visual analogue scales) and the mean tender point scores (measured with algometry) between any of the categories of patients. The mean algometer scores and symptom intensities being essentially the same for all three categories of patients may show that the mechanisms involved were due to the same abnormal process-inadequate thyroid hormone regulation of gene transcription. In primary and central hypothyroid patients, this would result from a frank hormone deficiency, and in euthyroid patients, possibly from cellular resistance to thyroid hormone due to mutations in the c-erbAβ1 gene.



Thyroid Science 2007Metabolic Failure as the Cause of Fibromyalgia Syndrome:Exploring the John C. Lowe Thesis Bjørn Johan Øverbye,MD

Norsk lege ser på Lowes fibromyalgi/stoffskifteforskning

Ömer Nuri Pamuk, Necati Çakir (2006) The frequency of thyroid antibodies in fibromyalgia patients and their relationship with symptoms

Abstract: We determined the frequency of thyroid autoantibodies in fibromyalgia (FM) patients and the relationship between FM symptoms and these antibodies. Euthyroid 128 FM patients, 64 rheumatoid arthritis (RA) patients, and 64 healthy control subjects were included in the study. The sociodemographic features and the clinical features of FM patients were determined. By using a visual analog scale, patients were questioned about the severity of FM-related symptoms. All patients were administered with Duke-Anxiety Depression (Duke-AD) scale, the physical function items of the fibromyalgia impact questionnaire scale. Thyroid autoimmunity was defined as the presence of detectable antithyroglobulin (TgAb) and/or antithyroid peroxidase (TPOAb) antibodies by the immunometric methods. Patients with a connective tissue disorder, hypo- or hyperthyroidism, and patients who had psychiatric treatment within the last 6 months were not included into the study. The frequencies of thyroid autoimmunity in FM (34.4%) and RA (29.7%) patients were significantly higher than controls (18.8%) (p<0.05). Twenty-six (20.3%) FM patients had positive TgAb and 31 (24.2%) had positive TPOAb. When patients with thyroid autoimmunity were compared to others, it was seen that the mean age, the percentage of postmenopausal patients, the frequency of dryness of the mouth, and the percentage of patients with a previous psychiatric treatment were higher in this group (p<0.05). FM patients had thyroid autoimmunity similar to the frequency in RA and higher than controls. Age and postmenopausal status seemed to be associated with thyroid autoimmunity in FM patients. The presence of thyroid autoimmunity had no relationship with the depression scores of FM patients.

(1998) W. Riedel, H. Layka, G. Neeck Secretory pattern of GH, TSH, thyroid hormones, ACTH, cortisol, FSH, and LH in patients with fibromyalgia syndrome following systemic injection of the relevant hypothalamic-releasing hormones

Summary: To study the hormonal perturbations in FMS patients we injected sixteen FMS patients and seventeen controls a cocktail of the hypothalamic releasing hormones: Corticotropin-releasing hormone (CRH), Thyrotropin-releasing hormone (TRH), Growth hormone-releasing hormone (GHRH), and Luteinizing hormone-releasing hormone (LHRH) and observed the hormonal secretion pattern of the pituitary together with the hormones of the peripheral endocrine glands. We found in FMS patients elevated basal values of ACTH and cortisol, lowered basal values of insulin-like growth factor I (IGF-I) and of triiodothyronine (T3), elevated basal values of follicle-stimulating hormone (FSH) and lowered basal values of estrogen. (….) We conclude that the observed pattern of hormonal deviations in FMS patients is a CNS adjustment to chronic pain and stress, constitutes a specific entity of FMS, and is primarily evoked by activated CRH neurons.

Jhon C. Lowe MA, DCa, Alan J. Reichman MDa & Jackie Yellin BAa

Clinical Bulletin of Myofascial Therapy 1996

The Process of Change During T3 Treatment for Euthyroid Fibromyalgia

A Double-Blind Placebo-Controlled Crossover Study  

Conclusion. Repeated administration and withdrawal of T3 corresponded to significant improvement and deterioration in fibromyalgia measures during this study. It is highly probable, then, that improvement in fibromyalgia status of our four patients was functionally related to their use of supraphysiologic dosages of T3 (effective range: 118.75-to-162.50 meg). These dosages were shown to be safe at 4-month follow-up. Further testing is necessary to establish long-term safety.


Laura Bazzichi, Alessandra Rossi, Tiziana Giuliano, Francesca De Feo, Camillo Giacomelli, Arianna Consensi, Antonio Ciapparelli, Giorgio Consoli, Liliana Dell’Osso,Stefano Bombardieri, Clinical Rheumatology, 2007 Association between thyroid autoimmunity and fibromyalgic disease severity

In conclusion, autoimmune thyroiditis is present in an elevated percentage of FM patients, and it has been associated with the presence of typical symptoms of the disease.

Washington Times rapporterte om studier på link mellom stoffskiftet og fibromyalgi

Merk at den danske fibromyaligforeningen er skeptisk til denne forskningen